Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; ...

Baseline factors linked to SLE flares during pregnancy included thrombocytopenia and a history of LN, while antimalarial therapy demonstrated protective effects.

Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, ...

Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...